Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of the patient’s own T cells so that they specifically recognize and destroy tumour cells. Considerable clinical success has been achieved using this technique in patients with lymphoid malignancies, but clinical studies that investigated treating solid tumours using this emerging technology have been disappointing. A number of developments might be able to increase the efficacy of CAR T cell therapy for treatment of prostate cancer, including improved trafficking to the tumour, techniques to overcome the immunosuppressive tumour microenvironment, as well as methods to enhance CAR T cell persistence, specificity and safety. Furthermore, CAR T cell therapy has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy, and could be applied as focal CAR T cell therapy for prostate cancer.
Chimeric antigen receptor (CAR) T cells, based on genetic engineering of the patient’s own T cells for targeted tumour cell lysis, have great potential as immunotherapy for prostate cancer.
Current developments focus on optimizing CAR T cells to improve trafficking to the tumour, overcome the immunosuppressive tumour microenvironment, and increase the cells’ persistence, specificity and safety.
Preclinical studies show that combination with standard therapies, such as androgen deprivation therapy, radiotherapy or chemotherapy, can be used to enhance the efficacy of CAR T cells against prostate cancer.
Intratumoural application of CAR T cells based on optimized imaging modalities could provide an effective and safe new focal therapeutic option for patients with localized prostate cancer.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Moris, L. et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur. Urol. 77, 614–627 (2020).
Pascale, M. et al. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression. BMC Cancer 17, 651 (2017).
Sathianathen, N. J., Konety, B. R., Crook, J., Saad, F. & Lawrentschuk, N. Landmarks in prostate cancer. Nat. Rev. Urol. 15, 627–642 (2018).
Cha, H. R., Lee, J. H. & Ponnazhagan, S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 80, 1615–1623 (2020).
Bilusic, M., Madan, R. A. & Gulley, J. L. Immunotherapy of prostate cancer: facts and hopes. Clin. Cancer Res. 23, 6764–6770 (2017).
Kiessling, A. et al. Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 4, 193–217 (2012).
Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).
Kantoff, P. W., Gulley, J. L. & Pico-Navarro, C. Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 35, 124–125 (2017).
Hansen, A. R. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29, 1807–1813 (2018).
Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).
Hernandez-Hoyos, G. et al. MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol. Cancer Ther. 15, 2155–2165 (2016).
Tran, B. et al. Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 38, TPS261–TPS261 (2020).
Elsallab, M., Levine, B. L., Wayne, A. S. & Abou-El-Enein, M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 21, e104–e116 (2020).
Frigault, M. J. & Maus, M. V. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J. Clin. Invest. 130, 1586–1594 (2020).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Patel, P. H. & Kockler, D. R. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42, 91–98 (2008).
Schellhammer, P. F. et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81, 1297–1302 (2013).
Gulley, J. L. et al. Phase III Trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 1051–1061 (2019).
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Salmaninejad, A. et al. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J. Cell Physiol. 234, 16824–16837 (2019).
Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K. & Najafi, R. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J. Cell Physiol. 234, 1313–1325 (2019).
Claps, M. et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes. Cancer Treat. Rev. 88, 102057 (2020).
Elia, A. R., Caputo, S. & Bellone, M. Immune checkpoint-mediated interactions between cancer and immune cells in prostate adenocarcinoma and melanoma. Front. Immunol. 9, 1786 (2018).
Thomsen, L. C. V. et al. A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 38, 3029 (2020).
Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE(R) antibody constructs — past developments and future directions. Immunol. Rev. 270, 193–208 (2016).
Campagne, O. et al. Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity. Clin. Cancer Res. 24, 2631–2641 (2018).
Li, H., Er Saw, P. & Song, E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol. Immunol. 17, 451–461 (2020).
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
Liu, D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J. Hematol. Oncol. 12, 113 (2019).
Knochelmann, H. M. et al. CAR T cells in solid tumors: blueprints for building effective therapies. Front. Immunol. 9, 1740 (2018).
Schmidts, A. & Maus, M. V. Making CAR T cells a solid option for solid tumors. Front. Immunol. 9, 2593 (2018).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
Jayaraman, J. et al. CAR-T design: elements and their synergistic function. EBioMedicine 58, 102931 (2020).
Fujiwara, K. et al. Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells 9, 1182 (2020).
Holzinger, A. & Abken, H. CAR T cells: a snapshot on the growing options to design a CAR. HemaSphere 3, e172 (2019).
Guedan, S., Calderon, H., Posey, A. D. Jr. & Maus, M. V. Engineering and design of chimeric antigen receptors. Mol. Therapy. Methods Clin. Dev. 12, 145–156 (2019).
Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164 (2013).
Andersch, L. et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer 19, 895 (2019).
Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28, 203–211 (2005).
Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947–953 (2019).
Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82–88 (2019).
Isakov, N. ITAMs: immunoregulatory scaffolds that link immunoreceptors to their intracellular signaling pathways. Recept. Channels 5, 243–253 (1998).
Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124, 1070–1080 (2014).
Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, e96976 (2018).
Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684 (2004).
Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).
Pule, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12, 933–941 (2005).
Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl Immunol. 8, e1049 (2019).
van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499–509 (2015).
Hartmann, J., Schussler-Lenz, M., Bondanza, A. & Buchholz, C. J. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol. Med. 9, 1183–1197 (2017).
Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity 44, 380–390 (2016).
Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T Cells. Cancer Cell 28, 415–428 (2015).
Alzubi, J. et al. PSMA-Directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Mol. Ther. Oncolytics 18, 226–235 (2020).
Abken, H. Costimulation engages the gear in driving CARs. Immunity 44, 214–216 (2016).
Foster, A. E. et al. Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40. Mol. Ther. 25, 2176–2188 (2017).
Shaw, J. et al. Tumor infiltration and cytokine biomarkers of prostate stem cell antigen (PSCA)-directed GOCAR-T cells in patients with advanced pancreatic tumors. J. Clin. Oncol. 38, 734 (2020).
Gargett, T. & Brown, M. P. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front. Pharmacol. 5, 235 (2014).
Chmielewski, M. & Abken, H. TRUCKs: the fourth generation of CARs. Expert. Opin. Biol. Ther. 15, 1145–1154 (2015).
Yu, S., Yi, M., Qin, S. & Wu, K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol. Cancer 18, 125 (2019).
Maus, M. V. & June, C. H. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin. Cancer Res. 22, 1875–1884 (2016).
Xie, G. et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59, 102975 (2020).
Bouchkouj, N. et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin. Cancer Res. 25, 1702–1708 (2019).
O’Leary, M. C. et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia. Clin. Cancer Res. 25, 1142–1146 (2019).
Jain, P. et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br. J. Haematol. 192, e38–e42 (2020).
Hegde, M. et al. Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma. J. Clin. Oncol. 35, 10508 (2017).
Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056 (2011).
Hou, B., Tang, Y., Li, W., Zeng, Q. & Chang, D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis. Markers 2019, 3425291 (2019).
Davis, M. I., Bennett, M. J., Thomas, L. M. & Bjorkman, P. J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl Acad. Sci. USA 102, 5981–5986 (2005).
Schmittgen, T. D., Teske, S., Vessella, R. L., True, L. D. & Zakrajsek, B. A. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int. J. Cancer 107, 323–329 (2003).
Wolf, P. et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 70, 562–569 (2010).
Carter, R. E., Feldman, A. R. & Coyle, J. T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl Acad. Sci. USA 93, 749–753 (1996).
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P. & Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256–2261 (1998).
Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur. Urol. 76, 469–478 (2019).
Kawakami, M. & Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57, 2321–2324 (1997).
Kasperzyk, J. L. et al. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 22, 2354–2363 (2013).
Beckett, M. L., Cazares, L. H., Vlahou, A., Schellhammer, P. F. & Wright, G. L. Jr. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin. Cancer Res. 5, 4034–4040 (1999).
Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).
Backhaus, P. et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur. J. Nucl. Med. Mol. Imaging 45, 860–877 (2018).
Ristau, B. T., O’Keefe, D. S. & Bacich, D. J. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol. 32, 272–279 (2014).
Ma, Q. et al. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61, 12–25 (2004).
Frigerio, B. et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur. J. Cancer 49, 2223–2232 (2013).
Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413–420 (2010).
Ma, Q., Gomes, E. M., Lo, A. S. & Junghans, R. P. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate 74, 286–296 (2014).
Stephan, M. T. et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440–1449 (2007).
Gade, T. P. et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65, 9080–9088 (2005).
Zuccolotto, G. et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS ONE 9, e109427 (2014).
Serganova, I. et al. Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 blockade. Mol. Ther. Oncolytics 4, 41–54 (2017).
Kloss, C. C. et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted Human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855–1866 (2018).
Reiter, R. E. et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95, 1735–1740 (1998).
Bahrenberg, G., Brauers, A., Joost, H. G. & Jakse, G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun. 275, 783–788 (2000).
Gu, Z. et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288–1296 (2000).
Han, K. R. et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J. Urol. 171, 1117–1121 (2004).
Lam, J. S. et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 11, 2591–2596 (2005).
Yang, X. et al. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications. Expert. Rev. Anticancer Ther. 14, 31–37 (2014).
Saeki, N., Gu, J., Yoshida, T. & Wu, X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin. Cancer Res. 16, 3533–3538 (2010).
Saffran, D. C. et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl Acad. Sci. USA 98, 2658–2663 (2001).
Priceman, S. J. et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology 7, e1380764 (2018).
Abate-Daga, D. et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum. Gene Ther. 25, 1003–1012 (2014).
Wu, D. et al. PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Res. 8, 3 (2020).
Ni, J. et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 31, 779–791 (2012).
Benko, G., Spajić, B., Krušlin, B. & Tomas, D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol. Oncol. 31, 468–474 (2013).
Poczatek, R. B. et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol. 162, 1462–1466 (1999).
Went, P. T. et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35, 122–128 (2004).
Zellweger, T. et al. Expression patterns of potential therapeutic targets in prostate cancer. Int. J. Cancer 113, 619–628 (2005).
Deng, Z., Wu, Y., Ma, W., Zhang, S. & Zhang, Y. Q. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 16, 1 (2015).
He, C. et al. Co-Expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion. Cancers 12, 1969 (2020).
Santoro, S. P. et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol. Res. 3, 68–84 (2015).
Liu, G., Rui, W., Zhao, X. & Lin, X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol. Immunol. 18, 1085–1095 (2021).
Gorchakov, A. A., Kulemzin, S. V., Kochneva, G. V. & Taranin, A. V. Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer. Eur. Urol. 77, 299–308 (2020).
Slovin, S. F. et al. Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). J. Immunother. Cancer 31, 72 (2013).
Junghans, R. P. et al. Phase I trial of anti-PSMA Designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate 76, 1257–1270 (2016).
Narayan, V. et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, TPS347 (2019).
Becerra, C. R. et al. Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: preliminary results from a dose escalation. J. Clin. Oncol. 37, 283 (2019).
Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell-associated neurotoxicity. Front. Immunol. 11, 577027 (2020).
Subklewe, M., von Bergwelt-Baildon, M. & Humpe, A. Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus. Med. Hemother 46, 15–24 (2019).
Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295–2306 (2017).
Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).
Cobb, D. A. & Lee, D. W. Cytokine release syndrome biology and management. Cancer J. 27, 119–125 (2021).
Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697–709 (2019).
Wang, Z. & Han, W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 6, 4 (2018).
Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731–738 (2018).
Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739–748 (2018).
Sun, S., Hao, H., Yang, G., Zhang, Y. & Fu, Y. Immunotherapy with CAR-Modified T cells: toxicities and overcoming strategies. J. Immunol. Res. 2018, 2386187 (2018).
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625–638 (2019).
Hunter, B. D. & Jacobson, C. A. CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. J. Natl Cancer Inst. 111, 646–654 (2019).
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81–85 (1997).
Langbein, T., Chaussé, G. & Baum, R. P. Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J. Nucl. Med. 59, 1172–1173 (2018).
Maleki Vareki, S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 6, 157 (2018).
Muthuswamy, R., Corman, J. M., Dahl, K., Chatta, G. S. & Kalinski, P. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+ T cells. Prostate 76, 1095–1105 (2016).
Di Stasi, A. et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392–6402 (2009).
Qian, D. Z. et al. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70, 433–442 (2010).
Hernandez, R. et al. Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy. J. Nucl. Med. 61, 36 (2020).
Jachetti, E. et al. Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol. Res. 6, 552–565 (2018).
Yuri, P. et al. Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients’ survival and responses to androgen deprivation therapies in Indonesian patients cohort. Prostate Int. 8, 62–69 (2020).
Watanabe, M. et al. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis. Prostate 79, 1658–1665 (2019).
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Wieser, R., Attisano, L., Wrana, J. L. & Massague, J. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Mol. Cell Biol. 13, 7239–7247 (1993).
Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249–258 (2017).
Mussolino, C., Alzubi, J., Pennucci, V., Turchiano, G. & Cathomen, T. Genome and epigenome editing to treat disorders of the hematopoietic system. Hum. Gene Ther. 28, 1105–1115 (2017).
Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).
Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl Med. 9, eaaj2013 (2017).
Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136–1147 (2021).
Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).
Sachdeva, M. et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. Nat. Commun. 10, 5100 (2019).
Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7, e1364828 (2017).
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).
Kailayangiri, S., Altvater, B., Wiebel, M., Jamitzky, S. & Rossig, C. Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers 12, 1075 (2020).
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018).
Schneider, D. et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl Med. 13, eabc6401 (2021).
Klesmith, J. R. et al. Retargeting CD19 chimeric antigen receptor T cells via engineered CD19-fusion proteins. Mol. Pharm. 16, 3544–3558 (2019).
Sachdeva, M., Duchateau, P., Depil, S., Poirot, L. & Valton, J. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294, 5430–5437 (2019).
Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087 (2019).
Xu, Y. et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov. 4, 62 (2018).
Kohl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T Cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559–568 (2018).
Mock, U. et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18, 1002–1011 (2016).
Alzubi, J. et al. Automated generation of gene-edited CAR T cells at clinical scale. Mol. Ther. Methods Clin. Dev. 20, 379–388 (2021).
Bailey, S. R. & Maus, M. V. Gene editing for immune cell therapies. Nat. Biotechnol. 37, 1425–1434 (2019).
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Kissick, H. T. et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc. Natl Acad. Sci. USA 111, 9887–9892 (2014).
Mercader, M. et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. USA 98, 14565–14570 (2001).
Isaacs, J. T., Furuya, Y. & Berges, R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin. Cancer Biol. 5, 391–400 (1994).
Ardiani, A., Gameiro, S. R., Kwilas, A. R., Donahue, R. N. & Hodge, J. W. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget 5, 9335–9348 (2014).
Krajewska, M. et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. 9, 4914–4925 (2003).
Tandon, M., Vemula, S. V. & Mittal, S. K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther. Targets 15, 31–51 (2011).
Petty, A. et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS ONE 7, e42120 (2012).
Salem, A. F. et al. Prostate cancer metastases are strongly inhibited by agonistic Epha2 ligands in an orthotopic mouse model. Cancers (Basel) 12, 2854 (2020).
Sanchez, C. et al. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 16, S121 (2013).
DeSelm, C. et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol. Ther. 26, 2542–2552 (2018).
Weiss, T., Weller, M., Guckenberger, M., Sentman, C. L. & Roth, P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 78, 1031–1043 (2018).
Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650–659 (2020).
Owens, K. & Bozic, I. Modeling CAR T-cell therapy with patient preconditioning. Bull. Math. Biol. 83, 42 (2021).
Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907–912 (2005).
Neelapu, S. S. CAR-T efficacy: is conditioning the key? Blood 133, 1799–1800 (2019).
Xu, J. et al. Combination therapy: a feasibility strategy for CAR-T cell therapy in the treatment of solid tumors. Oncol. Lett. 16, 2063–2070 (2018).
Ramakrishnan, R. et al. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 72, 5483–5493 (2012).
Motyka, B. et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103, 491–500 (2000).
Trapani, J. A. et al. A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J. Cell Biol. 160, 223–233 (2003).
Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729–741 (2013).
Martins, I. et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 8, 3723–3728 (2009).
Michaud, M. et al. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology 3, e944047 (2014).
Garg, A. D. et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front. Immunol. 6, 588 (2015).
Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
Proietti, E. et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101, 429–441 (1998).
Traverso, I. et al. Cyclophosphamide inhibits the generation and function of CD8+ regulatory T cells. Hum. Immunol. 73, 207–213 (2012).
Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336–344 (2004).
Jayram, G. & Eggener, S. E. Patient selection for focal therapy of localized prostate cancer. Curr. Opin. Urol. 19, 268–273 (2009).
Nassiri, N. et al. Focal therapy eligibility determined by magnetic resonance imaging/ultrasound fusion biopsy. J. Urol. 199, 453–458 (2018).
Ahdoot, M., Lebastchi, A. H., Turkbey, B., Wood, B. & Pinto, P. A. Contemporary treatments in prostate cancer focal therapy. Curr. Opin. Oncol. 31, 200–206 (2019).
van der Poel, H. G. et al. Focal therapy in primary localised prostate cancer: the european association of urology position in 2018. Eur. Urol. 74, 84–91 (2018).
Lovf, M. et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur. Urol. 75, 498–505 (2019).
Priceman, S. J. et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clin. Cancer Res. 24, 95–105 (2018).
Brown, C. E. et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072 (2015).
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016).
This work was supported by grants of the Federal Ministry of Education and Research (BMBF-01EO0813 to T.C.), the Horizon 2020 Programme of the European Commission (CARAT-667980 to T.C.), the Federal Ministry of Economic Affairs and Energy (BMWi-03THW15H04 to C.G. and T.C.), and the Research Commission of the Faculty of Medicine of the Albert-Ludwigs-University of Freiburg (no. WOL1111/16 to P.W. and T.C.).
T.C. has sponsored research collaborations with Cellectis and serves on the scientific advisory board of Excision BioTherapeutics. The other authors declare no competing interests.
Peer review information
Nature Reviews Urology thanks A. Gorchakov, D. Abate-Daga and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wolf, P., Alzubi, J., Gratzke, C. et al. The potential of CAR T cell therapy for prostate cancer. Nat Rev Urol 18, 556–571 (2021). https://doi.org/10.1038/s41585-021-00488-8